Kun ZhangHead of Intelligent medical group

PhD, Department of Biomedical Engineering, Peking University.

He joined CASI in 2015 and has worked as an investment analyst and investment manager, and now serves as VP and head of the Intelligent medical group. 

Mr. Zhang is responsible for the investment in Sciencare, iFLYTEK Healthcare, Wansi Healthcare, etc. and participated in the investment of high-quality projects such as Brandentech, Datsing Bio-tech, Topgen, Amcare, Canwell, Resproly, Techfields, Neupharma and ExcelMab. He focuses on investments in innovative drugs and medical devices.